Best deals to access real time data! |
|
CHART Trader
Monthly Subscription
for only
|
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Advaxis Inc | ADXS | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.0% | 0.328 | 0.00 | 0.00 | 0.00 | 0.328 | 05:34:59 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 0.328 | 0.345 | 0.017 | 4.93% | - | - |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 0.00 | USD |
Advaxis Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 8.10M | 24.71M | $ -66.52M | -19.74 | - | 20.30M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | 23.60% |
Advaxis News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ADXS Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol [m] | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.34 | 0.36 | 0.275 | 0.3250 | 7M | -0.012 | -3.53% |
| 1 Month | 0.29 | 0.6 | 0.202 | 0.3311 | 12M | 0.038 | 13.10% |
| 3 Months | 0.664 | 0.699 | 0.202 | 0.3352 | 6M | -0.336 | -50.60% |
| 6 Months | 3.3 | 4.21 | 0.202 | 0.4335 | 3M | -2.972 | -90.06% |
| 1 Year | 0.6791 | 10.8 | 0.181 | 0.6529 | 2M | -0.3511 | -51.70% |
| 3 Years | 9.12 | 10.88 | 0.181 | 2.2391 | 1M | -8.792 | -96.40% |
| 5 Years | 2.99 | 30.13 | 0.181 | 6.3360 | 1M | -2.662 | -89.03% |
Advaxis Description
| Advaxis Inc is a clinical stage biotechnology company operating in the United States. It focuses on discovery, development, and commercialization of proprietary Lm (Listeria monocytogenes)-LLO (Listeriolysin O) cancer immunotherapies. These immunotherapies are based on a platform technology which utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. The company's immunotherapy products based on Lm-LLO immunotherapy are Axalimogene filolisbac (AXAL) which targets Human Papilloma Virus (HPV) - associated cancers and ADXS-PSA which targets Prostate Specific Antigen (PSA) associated with prostate cancer. |
